Azenta

Azenta, Inc. is a provider of life sciences sample exploration and management solutions for the life sciences market. It operates through the Life Sciences Products and Life Sciences Services segments. The Life Sciences Products segment is involved in automated cold storage solutions for biological and chemical compound samples. The Life Sciences Services segment focuses on the solutions addressing the many needs of customers in the area of genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development markets. The company was founded in 1978 and is headquartered in Burlington, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Azenta (AZTA) reports robust Q1 earnings, eyes strategic investments

Azenta's Q1 results showcase strong revenue growth and strategic acquisitions, positioning the company for future success. While facing challenges in certain segments, the focus on investments and efficiencies presents opportunities for growth and margin improvement.

Azenta reports mixed Q2 results, focuses on growth initiatives

Azenta's Q2 2023 performance was mixed, with challenges in B Medical impacting revenue but Services business showing resilience and genomics revenue rebounding positively.
Strategic acquisitions, cost actions, and a realignment initiative aim to enhance profitability and drive growth, with a focus on accelerating organic growth and expanding Services business.
Despite margin decreases and revenue challenges, Azenta remains focused on growth initiatives, addressing concerns about distractions and emphasizing opportunities for expansion and profitability.
Management's outlook includes revised revenue guidance, adjusted EBITDA margin expectations, and a commitment to driving profitability through growth initiatives and cost actions.

Azenta reports solid Q3 earnings, eyes growth in China

Azenta's Q3 performance showcased positive financial indicators, with notable growth in key segments and a focus on cost reduction initiatives.
While facing challenges in the Products segment and market share determination, the company remains optimistic about growth opportunities in China and key service offerings.
With a strong focus on sales, marketing, and cost reduction, Azenta aims to sustain its growth trajectory and enhance profitability in the future.

Azenta reports robust Q4 earnings, eyes growth opportunities in 2024

Azenta's Q4 performance was strong, with positive outlook for fiscal 2024 and a commitment to share repurchase.
While facing challenges in gross margins, the company sees opportunities in organic growth and margin expansion.
Strengthening Cell and Gene Therapy business and operational improvements are key focus areas for future growth.
Overall, Azenta remains confident in its ability to outperform the market and enhance profitability.

Azenta reports Q1 revenue decline but sees growth opportunities ahead

Azenta's Q1 performance showed mixed results with revenue decline but growth in key segments. The company remains focused on maintaining guidance and balancing revenue throughout the year.
While facing challenges in B Medical revenue and market dynamics, Azenta has opportunities in sample retrieval programs and financial performance improvements.
Overall, Azenta's strategic focus on key segments and opportunities for growth position the company well for future success, despite current challenges and market conditions.

Azenta reports solid Q2 earnings, eyes growth in China

Azenta's Q2 performance showed revenue growth and improved margins despite challenges.
The company's strengths lie in strong segment growth and market outperformance in China.
Challenges include lower guidance for B Medical and softness in the Instruments segment.
Opportunities arise from pursuing Ascend 2026 plan, NGS shift, and China market growth.

Azenta reports strong Q3 performance and operational profitability growth

Azenta's Q3 results reflect a positive trajectory with revenue growth and improved profitability.
Strategic focus on key segments and the Ascend 2026 program are driving operational efficiency and margin expansion.
While challenges exist in certain segments, opportunities for growth and optimization present a promising outlook for Azenta.

Azenta reports resilient Q4 performance and outlines growth strategies

Azenta's Q4 2024 earnings call highlighted strong financial results, strategic decisions, and future growth initiatives amidst market challenges and uncertainties.
The company's focus on core businesses, competitive strengths in Sample Management Solutions and Multiomics, and commitment to shareholder value enhancement position it for success in 2025.
While facing revenue declines and market-related queries, Azenta's proactive approach to portfolio optimization, operational efficiency, and capital allocation sets the stage for sustainable growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Azenta (AZTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Azenta (AZTA) Surges 7.2%: Is This an Indication of Further Gains?

Concentra Group Holdings Parent Inc

Envestnet

Flex

Myers

Select Medical Holdings

NEW YORK , Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE: ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions.

Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

BURLINGTON, Mass. , Nov. 14, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Stephens Annual Investment Conference, on Wednesday November 20, 2024, which includes a presentation beginning at 1:00 pm CT.

Azenta to Participate in Stephens Annual Investment Conference

Azenta, Inc. (NASDAQ:AZTA ) Q4 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations John Marotta - President and Chief Executive Officer Herman Cueto - Executive Vice President and Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Vijay Kumar - Evercore ISI Jacob Johnson - Stephens Andrew Cooper - Raymond James Matt Stanton - Jefferies Lucas Baranowski - KeyBanc Capital Operator Greetings and welcome to the Azenta Fourth Quarter 2024 Financial Results. During the presentation, all lines will be in a listen-only mode.

Azenta, Inc. (AZTA) Q4 2024 Earnings Call Transcript

Azenta (AZTA) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.13 per share a year ago.

Azenta (AZTA) Q4 Earnings Top Estimates

FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and Multiomics FY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points Pursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitability Announces appointment of Lawrence Y. Lin as Chief Financial Officer; Herman Cueto to remain as advisor to ensure smooth transition BURLINGTON, Mass.

Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO

BURLINGTON, Mass. , Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes.

Azenta Announces Fiscal 2024 Fourth Quarter and Full Year Earnings Conference Call and Webcast

Brightview Holdings

LiveWire Group Inc

William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass.

Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

BURLINGTON, Mass. , Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications.

Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test

Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass. , Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company"), today announced that John P.

AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

BURLINGTON, Mass. , Aug. 12, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences will be hosting its 25th anniversary and the launch of its annual GENEWIZ Week event on September 16 - 20.

GENEWIZ from Azenta Life Sciences Celebrates 25 Years of Advancing Scientific Discoveries at GENEWIZ Week Event

Azenta, Inc. (NASDAQ:AZTA ) Q3 2024 Results Conference Call August 6, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations Steve Schwartz - President and Chief Executive Officer Herman Cueto - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Sophia Knopp - Evercore ISI Noah Lewis - Raymond James Matt Stanton - Jefferies Lucas Baranowski - KeyBanc Capital Operator Greetings, and welcome to the Azenta Third Quarter 2024 Financial Results. [Operator Instructions].

Azenta, Inc. (AZTA) Q3 2024 Earnings Call Transcript

Azenta (AZTA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.13 per share a year ago.

Azenta (AZTA) Q3 Earnings and Revenues Top Estimates

BURLINGTON, Mass. , Aug. 6, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2024.

Azenta Reports Third Quarter Results for Fiscal 2024, Ended June 30, 2024

BURLINGTON, Mass. , Aug. 5, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, on Monday, August 12, 2024.

Azenta to Participate in 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for

Investors need to pay close attention to Azenta (AZTA) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Azenta (AZTA) Stock?

BURLINGTON, Mass. , July 24, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2024 earnings which ended on June 30, 2024, on Tuesday, August 6, 2024, after the market closes.

Azenta Announces Fiscal 2024 Third Quarter Earnings Conference Call and Webcast

Azenta will provide proteomics technology profiling on up to 20,000 individuals. BURLINGTON, Mass.

FinnGen Selects Azenta to Propel Personalized Medicine for Population Health Study

Afya Ltd

Apogee Enterprises

B2Gold

Kinross Gold

BTG, APOG, AZTA, AFYA and KGC have been added to the Zacks Rank #1 (Strong Buy) List on July 16, 2024.

New Strong Buy Stocks for July 16th

Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services Provider for its Inflammatory Bowel Disease (IBD) CAPTURE and SIRQC Clinical Registries BURLINGTON, Mass. , June 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Crohn's & Colitis Foundation (the "Foundation") as its sample management services provider for two of its large-scale prospective research cohorts, CAPTURE IBD and IBD SIRQC, which investigate pediatric and surgical care for Crohn's disease and ulcerative colitis.

Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research

BURLINGTON, Mass. , May 23, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Jefferies Global Healthcare Conference in New York, NY, on Wednesday, June 5, 2024, which includes a presentation beginning at 11:00 am ET.

Azenta to Participate in the Jefferies Global Healthcare Conference

iRobot

Rockwell Automation

Robotics and automation go hand in hand. Inflationary pressures have been plaguing both consumers and business owners.

Stock Market Crash Warning: Don't Get Caught Holding These 3 Robotics Stocks

BURLINGTON, Mass. , May 13, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further in the UK market.

Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK

Azenta, Inc. (NASDAQ:AZTA ) Q2 2024 Results Conference Call May 8, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations Steve Schwartz - President and Chief Executive Officer Herman Cueto - Chief Financial Officer Conference Call Participants David Saxon - Needham Hannah Hefley - Stephens Vijay Kumar - Evercore ISI Yuan Zhi - B. Riley Matt Stanton - Jefferies Operator Greetings, and welcome to the Azenta Second Quarter 2024 Financial Results.

News for Azenta Stock (AZTA)